Grants and Contributions:
Title:
Development of Pharmacological Compounds to Overcome Respiratory Depression
Agreement Number:
904073
Agreement Value:
$72,000.00
Agreement Date:
Apr 1, 2018 - Apr 30, 2019
Description:
The Firm is developing a pharmacological therapy using drugs that target the alpha2beta2 subtype of nicotonic acetylcholine receptor to counter respiratory depression associated with opiates (e.g. fentanyl), propofol, alcohol, barbiturates, apnea of prematurity, obstructive and central sleep apnea, brain and spinal cord damage, and genetic disorders affecting breathing (e.g. Pompe Disease). They will perform a systematic series of pre-clinical studies using rodent models to determine the most effective candidate compounds to be tested in early stage clinical trials.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5R 3P2
Reference Number:
172-2018-2019-Q1-904073
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
851677955
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amendment value is 500 dollars.
Amendment Date
Apr 8, 2019
Recipient's Legal Name:
Progress Scientific Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: